Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03060785 · ClinicalTrials.gov registry record · Phase 1
Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03060785: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT03060785 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03060785, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is an open-label, steady-state study of Tenofovir (TFV) and Emtricitabine (FTC) pharmacokinetics (PK) in transgender women taking feminizing hormones. Half of the participants will be transgender women on feminizing hormones, the other half will be male volunteers not taking any hormone therapy.
Interventions
- DRUG Tenofovir Disoproxil Fumarate/Emtricitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-03-08 |
| Est. Completion | 2018-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03060785
The ClinicalTrials.gov registry entry for NCT03060785 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenofovir Disoproxil Fumarate/Emtricitabine is the first listed.
NCT03060785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03060785 about?
NCT03060785 is a clinical study titled "Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women". This is an open-label, steady-state study of Tenofovir (TFV) and Emtricitabine (FTC) pharmacokinetics (PK) in transgender women taking feminizing hormones. Half of the participants will be transgender women on feminizing hormones, the other half will be male volunteers not taking any hormone therapy...
What is the current status of trial NCT03060785?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-03-08. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT03060785?
The interventions under investigation include: Tenofovir Disoproxil Fumarate/Emtricitabine (DRUG).
Who is sponsoring clinical trial NCT03060785?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.